Heather M Walline1, Chris Komarck2, Jonathan B McHugh3, Serena A Byrd4, Matthew E Spector2, Samantha J Hauff5, Martin P Graham2, Emily Bellile6, Jeffrey S Moyer2, Mark E Prince2, Gregory T Wolf2, Douglas B Chepeha2, Francis P Worden7, Matthew H Stenmark8, Avraham Eisbruch8, Carol R Bradford2, Thomas E Carey2. 1. Cancer Biology Program, Program in the Biomedical Sciences, Rackham Graduate School, University of Michigan, Ann Arbor. 2. Department of Otolaryngology/Head and Neck Surgery, University of Michigan, Ann Arbor. 3. Department of Pathology, University of Michigan, Ann Arbor. 4. University of Michigan Medical School, Ann Arbor8currently with the Department of Otolaryngology/Head and Neck Surgery, St Louis University, St Louis, Missouri. 5. University of Michigan Medical School, Ann Arbor9currently with the Department of Otolaryngology/Head and Neck Surgery, University of California, San Diego. 6. Cancer Biostatistics, University of Michigan Comprehensive Cancer Center, Ann Arbor. 7. Division of Medical Oncology, Department of Medicine, University of Michigan, Ann Arbor. 8. Department of Radiation Oncology, University of Michigan, Ann Arbor.
Abstract
IMPORTANCE: Human papillomaviruses are now recognized as an etiologic factor in a growing subset of head and neck cancers and have critical prognostic importance that affects therapeutic decision making. There is no universally accepted gold standard for high-risk HPV (hrHPV) assessment in formalin-fixed, paraffin-embedded (FFPE) tissue specimens, nor is there a clear understanding of the frequency or role of hrHPV in sites other than oropharynx. OBJECTIVE: To determine the optimal assessment of hrHPV in FFPE head and neck tumor tissue specimens. DESIGN, SETTING, PARTICIPANTS: In the setting of a large Midwestern referral center, assessment of hrHPV by p16 immunohistochemical staining, in situ hybridization, and polymerase chain reaction (PCR)-MassArray (PCR-MA), with L1 PGMY-PCR and sequencing to resolve method discordance, was conducted for 338 FFPE oropharyngeal, nasopharyngeal, and oral cavity tumor tissue specimens. Relative sensitivity and specificity were compared to develop a standard optimal test protocol. Tissue specimens were collected from 338 patients with head and neck cancer treated during the period 2001 through 2011 in the departments of Otolaryngology, Radiation Oncology, and Medical Oncology. INTERVENTION: Patients received standard therapy. MAIN OUTCOMES AND MEASURES: Optimal hrHPV identification, detection, and activity in head and neck cancers. RESULTS: Using combined PCR-MA with L1 PGMY-PCR and sequencing for conclusive results, we found PCR-MA to have 99.5% sensitivity and 100% specificity, p16 to have 94.2% sensitivity and 85.5% specificity, and in situ hybridization to have 82.9% sensitivity and 81.0% specificity. Among HPV-positive tumors, HPV16 was most frequently detected, but 10 non-HPV16 types accounted for 6% to 50% of tumors, depending on the site. Overall, 86% of oropharynx, 50% of nasopharynx, and 26% of oral cavity tumors were positive for hrHPV. CONCLUSIONS AND RELEVANCE: PCR-MA has a low DNA (5 ng) requirement effective for testing small tissue samples; high throughput; and rapid identification of HPV types, with high sensitivity and specificity. PCR-MA together with p16INK4a provided accurate assessment of HPV presence, type, and activity and was determined to be the best approach for HPV testing in FFPE head and neck tumor tissue specimens.
IMPORTANCE: Human papillomaviruses are now recognized as an etiologic factor in a growing subset of head and neck cancers and have critical prognostic importance that affects therapeutic decision making. There is no universally accepted gold standard for high-risk HPV (hrHPV) assessment in formalin-fixed, paraffin-embedded (FFPE) tissue specimens, nor is there a clear understanding of the frequency or role of hrHPV in sites other than oropharynx. OBJECTIVE: To determine the optimal assessment of hrHPV in FFPE head and neck tumor tissue specimens. DESIGN, SETTING, PARTICIPANTS: In the setting of a large Midwestern referral center, assessment of hrHPV by p16 immunohistochemical staining, in situ hybridization, and polymerase chain reaction (PCR)-MassArray (PCR-MA), with L1 PGMY-PCR and sequencing to resolve method discordance, was conducted for 338 FFPE oropharyngeal, nasopharyngeal, and oral cavity tumor tissue specimens. Relative sensitivity and specificity were compared to develop a standard optimal test protocol. Tissue specimens were collected from 338 patients with head and neck cancer treated during the period 2001 through 2011 in the departments of Otolaryngology, Radiation Oncology, and Medical Oncology. INTERVENTION: Patients received standard therapy. MAIN OUTCOMES AND MEASURES: Optimal hrHPV identification, detection, and activity in head and neck cancers. RESULTS: Using combined PCR-MA with L1 PGMY-PCR and sequencing for conclusive results, we found PCR-MA to have 99.5% sensitivity and 100% specificity, p16 to have 94.2% sensitivity and 85.5% specificity, and in situ hybridization to have 82.9% sensitivity and 81.0% specificity. Among HPV-positive tumors, HPV16 was most frequently detected, but 10 non-HPV16 types accounted for 6% to 50% of tumors, depending on the site. Overall, 86% of oropharynx, 50% of nasopharynx, and 26% of oral cavity tumors were positive for hrHPV. CONCLUSIONS AND RELEVANCE: PCR-MA has a low DNA (5 ng) requirement effective for testing small tissue samples; high throughput; and rapid identification of HPV types, with high sensitivity and specificity. PCR-MA together with p16INK4a provided accurate assessment of HPV presence, type, and activity and was determined to be the best approach for HPV testing in FFPE head and neck tumor tissue specimens.
Authors: P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple Journal: J Clin Microbiol Date: 2000-01 Impact factor: 5.948
Authors: J P Klussmann; S J Weissenborn; U Wieland; V Dries; J Kolligs; M Jungehuelsing; H E Eckel; H P Dienes; H J Pfister; P G Fuchs Journal: Cancer Date: 2001-12-01 Impact factor: 6.860
Authors: Jessica H Maxwell; Bhavna Kumar; Felix Y Feng; Jonathan B McHugh; Kitrina G Cordell; Avraham Eisbruch; Francis P Worden; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Theodoros N Teknos; Douglas B Chepeha; Jay Stoerker; Heather Walline; Thomas E Carey; Carol R Bradford Journal: Head Neck Date: 2010-05 Impact factor: 3.147
Authors: Anthony C Nichols; Sandeep S Dhaliwal; David A Palma; John Basmaji; Corina Chapeskie; Samuel Dowthwaite; Jason H Franklin; Kevin Fung; Keith Kwan; Brett Wehrli; Chris Howlett; Iram Siddiqui; Marina I Salvadori; Eric Winquist; Scott Ernst; Sara Kuruvilla; Nancy Read; Varagur Venkatesan; Biljana Todorovic; J Alex Hammond; James Koropatnick; Joe S Mymryk; John Yoo; John W Barrett Journal: J Otolaryngol Head Neck Surg Date: 2013-02-01
Authors: Lisa A Peterson; Emily L Bellile; Gregory T Wolf; Shama Virani; Andrew G Shuman; Jeremy M G Taylor; Laura S Rozek Journal: Head Neck Date: 2016-07-19 Impact factor: 3.147
Authors: Jeffrey M Vainshtein; Matthew E Spector; Jonathan B McHugh; Ka Kit Wong; Heather M Walline; Serena A Byrd; Christine M Komarck; Mohannad Ibrahim; Matthew H Stenmark; Mark E Prince; Carol R Bradford; Gregory T Wolf; Scott McLean; Francis P Worden; Douglas B Chepeha; Thomas Carey; Avraham Eisbruch Journal: Oral Oncol Date: 2014-02-22 Impact factor: 5.337
Authors: Jason J Ong; Tim Read; Marcus Chen; Sandra Walker; Matthew Law; Catriona Bradshaw; Suzanne M Garland; Sepehr N Tabrizi; Alyssa Cornall; Andrew Grulich; Jane Hocking; Christopher K Fairley Journal: J Clin Microbiol Date: 2014-04-09 Impact factor: 5.948
Authors: Heather M Walline; Thomas E Carey; Christine M Goudsmit; Emily L Bellile; Gypsyamber D'Souza; Lisa A Peterson; Jonathan B McHugh; Sara I Pai; J Jack Lee; Dong M Shin; Robert L Ferris Journal: Mol Cancer Res Date: 2016-11-29 Impact factor: 5.852
Authors: Kyle K VanKoevering; Emily Marchiano; Heather M Walline; Thomas E Carey; Jonathan B McHugh; J Chad Brenner; Christine M Goudsmit; Emily Belille; Matthew E Spector; Andrew G Shuman Journal: Otolaryngol Head Neck Surg Date: 2017-09-26 Impact factor: 3.497
Authors: Lisa M Pinatti; Hana N Sinha; Collin V Brummel; Christine M Goudsmit; Timothy J Geddes; George D Wilson; Jan A Akervall; Chad J Brenner; Heather M Walline; Thomas E Carey Journal: Head Neck Date: 2020-10-19 Impact factor: 3.147
Authors: Matthew H Stenmark; Jonathan B McHugh; Matthew Schipper; Heather M Walline; Christine Komarck; Felix Y Feng; Francis P Worden; Gregory T Wolf; Douglas B Chepeha; Mark E Prince; Carol R Bradford; Suresh K Mukherji; Avraham Eisbruch; Thomas E Carey Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-01 Impact factor: 7.038
Authors: Adam Scheel; Emily Bellile; Jonathan B McHugh; Heather M Walline; Mark E Prince; Susan Urba; Gregory T Wolf; Avraham Eisbruch; Francis Worden; Thomas E Carey; Carol Bradford Journal: Laryngoscope Date: 2016-06-27 Impact factor: 3.325